Progenics Pharmaceuticals Inc (PGNX)

Establishes Automated BSI as Prognostic Biomarker for Overall Survival

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DMLP, GPL, HZN, LPSN Downgrades: AGLE, AKAM, ASFI, FOR, HTLD, LLY, NTZ, OSTK, PGNX, PWR, RECN, TRNC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 928,274 share increase in total short interest for Progenics Pharmaceuticals, Inc. , to 7,977,161, an increase of 13.17% since 03/31/2017.

In trading on Friday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $7.82, changing hands as low as $7.67 per share.

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 2,093,733 share decrease in total short interest for Progenics Pharmaceuticals, Inc. , to 7,048,887, a decrease of 22.90% since 03/15/2017.

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

I've learned that emotions have little use at a poker table; they don't in the stock market, either.

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the November 17th expiration.

I'm still enthusiastic about the sector, but it is critical to also be prudent.

I'm still enthusiastic about the sector, but it is critical to also be prudent.

Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the March 17th expiration.

Investors considering a purchase of Progenics Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $8.79/share, might benefit from considering selling puts among the alternative strategies at their disposal.

This biopharma company's Relistor drug should send revenues sharply higher this year.

This biopharma company's Relistor drug should send revenues sharply higher next year.